Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

@article{Aisen2012SymptomaticAN,
  title={Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.},
  author={Paul S. Aisen and Jeffrey Cummings and L. S. Schneider},
  journal={Cold Spring Harbor perspectives in medicine},
  year={2012},
  volume={2 3},
  pages={a006395}
}
In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression… CONTINUE READING